(VIANEWS) – Arcturus Therapeutics’ (NASDAQ: ARCT) shares surged 23.09% to EUR23.88 at 21:33 EST on Wednesday, following their upward trajectory since Tuesday’s session and as the stock market as a whole showed positivity – rising 0.24% overall and reaching EUR14,128.19!
Arcturus Therapeutics closed at EUR19.40 on November 25, 48.61% below its 52-week high of EUR37.75.
Market Cap: EUR4.4 Billion
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is a biotech company focused on late-stage clinical mRNA medicines and vaccines. Their primary focus is the development of vaccines and treatments for infectious diseases, liver, and respiratory rare diseases using LUNAR lipid-mediated delivery and STARR mRNA as unique technology platforms; Arcturus currently has three products under trial utilizing these platforms, such as ARCT-810 (LUNAR-OTC) which is in Phase 2 trials for ornithine transcarbamylase deficiency; ARCT154 (LUNAR-COVID-19), and ARCT-032 (LUNAR-CF). Established in 2013 with headquarters located in San Diego California
Yearly Analysis
Based on the available information, here is a concise investment outlook for Arcturus Therapeutics:
**Overview**
Arcturus Therapeutics (ARCT) is currently trading at EUR23.88, significantly below its 52-week high of EUR37.75 but higher than its low of EUR14.21. Arcturus is anticipated to experience negative 33.7% sales growth this year before experiencing moderate 6.1% expansion the following year; their EBITDA stands at -9.12.
At its current market price and expected sales growth projections, Arcturus Therapeutics presents a high-risk investment. A negative sales growth for this year raises significant concern as it may indicate potential challenges facing Arcturus in terms of profitability and performance.
However, expected growth of 6.1% over the coming year could signal a potential turnaround for this company. Investors should take note that EBITDA remains negative; this should serve as a red flag.
Overall, Arcturus Therapeutics can be considered a high-risk investment opportunity that may present potential for long-term growth. Investors interested in this stock should closely follow its performance and financial health over the coming months in order to make an informed decision regarding investing in this stock.
Technical Analysis
Arcturus Therapeutics’ Stock Price Movements (ARCT)Arcturus Therapeutics’ share prices have experienced a downward trend recently, dropping below both its 50-day and 200-day moving averages – this could signal bearish market conditions. Notably, trading volume has seen an upward trend, reaching 859,796 today – 139.53% higher than its average volume of 358,946! An increase in trading activity could indicate that investors are taking a closer look at a stock, which could potentially result in its price reversal. Investors should also keep an eye on Arcturus Therapeutics’s volatility, which has fluctuated within its negative range over the last week, month and quarter. Furthermore, its stochastic oscillator indicates it may currently be overbought and may lead to a short-term correction in price movements. Overall, investors should keep tabs on Arcturus Therapeutics stock price movements closely as well as adopt a cautious investment approach due to current market conditions.
Quarter Analysis
Arcturus Therapeutics experienced significant sales growth of 363.7% for this quarter; however, their estimates for next quarter indicate potential decline in sales with negative 78.2% growth projection for next quarter and negative 126.9% forecasted for following quarter.
Additionally, year-on-year quarterly revenue growth has dropped 61.2% over the past twelve months to reach $264.47M currently.
Arcturus Therapeutics may be experiencing challenges to its growth trajectory in the near term, and investors should carefully evaluate this information and conduct additional research before making investment decisions.
Equity Analysis
Arcturus Therapeutics has demonstrated strong profitability based on the information available, boasting a trailing twelve month earnings per share (EPS) of EUR3.03. Additionally, Arcturus Therapeutics boasts an attractive trailing twelve month price-earnings ratio of 7.88; this indicates the stock may be undervalued compared with similar companies in its industry. Lastly, with an impressive return on equity (ROE) percentage of 35.22% this indicates strong profitability as well.
Arcturus Therapeutics appears to be a profitable company with a relatively low PE ratio, making it an attractive opportunity for investors looking for undervalued stocks with proven profitability. A detailed examination of Arcturus Therapeutics’ financial statements, industry trends and competitive landscape is needed in order to make an informed investment decision.
More news about Arcturus Therapeutics (ARCT).
